<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "pertuzumab inj VIAL">
<dose><value>840</value>
<value>420</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>30 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
</frequency>
<instruction><value>Administer dose diluted in 250 mL 0.9% sodium chloride over 60 minutes.</value>
<value>Administer dose diluted in 250 mL 0.9% sodium chloride over 30 to 60 minutes.</value>
</instruction>
<volume><value>14 mL</value>
</volume>
<units><value>mg</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Metastatic Breast Cancer. Observe patient for a 60 minute period post-infusion.</value>
<value>Metastatic Breast Cancer. Observe patient for a 30 minute period post-infusion. If the time between infusions is less than 6 weeks, the 420 mg dose may be continued. If the time between infusions is 6 weeks or more, a dose of 840 mg pertuzumab should be re-administered and then subsequent dosing would continue at 420 mg.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6322</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>DEF</value>
</AHSFormularyStatus>
<HighAlert><value>HIGH ALERT MEDICATION</value>
</HighAlert>
</drug>